¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Linton shunt"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • shunt
    1. Áö¸§±æ, »çÀÕ±æ 2. ¼ÇÆ®, Áö¸§
  • shunt circuit
    ¼ÇƮȸ·Î
  • shunt effect
    Áö¸§±æÈ¿°ú, ¼ÇƮȿ°ú
  • shunt malfunction
    Áö¸§±æ±â´ÉºÒ·®, ¼ÇÆ®±â´ÉºÒ·®
  • shunt operation
    ¼ÇÆ®¼ö¼ú, Áö¸§¼ú
  • ventriculoatrial shunt
    ³ú½Ç½É¹æ¼ÇÆ®
  • ventriculoperitoneal shunt
    ³ú½Çº¹°­¼ÇÆ®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • subarachnoid ureteral shunt
    °Å¹Ì¸·¹Ø¿ä°üÁö¸§±æ, °Å¹Ì¸·¹Ø¿ä°üÁö¸§¼ú
  • subduro-atrial shunt
    ³ú°æ¸·¹Ø½É¹æÁö¸§¼ú
  • subduro-peritoneal shunt
    ³ú°æ¸·¹Ø¹è¾ÈÁö¸§¼ú
  • ventriculoatrial shunt
    ³ú½Ç½É¹æÁö¸§¼ú
  • ventriculocaval shunt
    ³ú½Ç»ó´ëÁ¤¸ÆÁö¸§¼ú
  • ventriculosubarachnoid shunt
    ³ú½Ç°Å¹Ì¸·¹ØÁö¸§¼ú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • right to left shunt
    Á¿ì´Ü¶ô(ñ§éÓÓ­Õ©).
  • right to left shunt
    Á¿ì´Ü¶ô(ñ§éÓÓ­Õ©)
  • right-to-left shunt
    ¿ìÁÂ¼ÇÆ®(¿ìÁ¡­)
  • shunt
    ¼ÇÆ®(¡­), ´Ü¶ô(Ó­Õ©), ¹®ÇÕ(Ùüùê)
  • shunt =short circuit
    ¼ÇÆ®, ´Ü¶ô (Ó­Õ©).
  • shunt effect
    ¼ÇƮȿ°ú, ´Ü¶ôÈ¿°ú(¡­üùÍý).
  • shunt equation
    ¼ÇÆ®¹æÁ¤½Ä.
  • shunt operation
    ´Ü¶ô¼ö¼ú, ¹®ÇÕ¼ö¼ú.
  • splenorenal shunt
    ºñ½ÅÁ¤¸Æ¹®ÇÕ¼ú(ºñ½ÅÁ¤¸Æ¹®ÇÕ¼ú).
  • subarachnoid ureteral shunt
    °Å¹Ì¸·Çϰ­´¢°ü´Ü¶ô(¡­Ë·èñηӭթ).
  • subarachnoid ureteral shunt
    °Å¹Ì¸·Çϰ­´¢°ü´Ü¶ô(¡­Ë·èñηӭթ)
  • transjugular intrahepatic portosystemic shunt
    °æ°æÁ¤¸Æ°£³»¹®¸ÆÁ¤¸Æ´Ü¶ô¼ú
  • ventriculoatrial shunt
    ³ú½Ç½É¹æ´Ü¶ô(ÒàãøãýÛ®Ó­Õ©).
  • ventriculoauricular shunt
    ³ú½Ç½ÉÀÌ(¡­ãýì¼)´Ü¶ô.
  • ventriculocaval shunt
    ³ú½Ç»ó´ëÁ¤¸Æ´Ü¶ô(¼ú)(Òàãøß¾ÓÞð¡ØæÓ­Õ©âú).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
VU shunt Ventriculo-Ureteral shunt
SP sacroposterior; sacrum to pubis; salivary progesterone; schizotypal personality; semi-private [room]...
PEEP Positive End-Expiratory Pressure
  ? Ix
    1. PaO2 < 60 mmHg, ...
TIPSS Transjugular Intrahepatic Portosystemic Stant, Shunt
AVS aortic valve stenosis; arteriovenous shunt; auditory vocal sequencing
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
TIPS Transjugular Intrahepatic Portosystemic Shunt
TIPSS Transjugular Intrahepatic Portosystemic Stent Shunt
PSS porto-systemic shunt
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
Warburg-Dickens-Horecker shunt <biochemistry> A pathway of hexose oxidation in which glucose-6-phosphate undergoes two successive oxidations by NADP, the final one being an oxidative decarboxylation to form a pentose phosphate.
Diverges from this when glucose-6-phosphate is oxidized to ribose 5 phosphate by the enzyme glucose-6 phosphate dehydrogenase. This step reduces NADP to NADPH, generating a source of reducing power in cells for use in reductive biosyntheses.
In plants, part of the pathway functions in the formation of hexoses from carbon dioxide in photosynthesis. Also important as source of pentoses, for example for nucleic acid biosynthesis. This pathway is the main metabolic pathway in neutrophils, congenital deficiency in the pathway produces sensitivity to infection.
Alternative metabolic route to Embden Meyerhof pathway for breakdown of glucose.
(18 Nov 1997)
Warburg-Lipmann-Dickens-Horecker shunt <biochemistry> A pathway of hexose oxidation in which glucose-6-phosphate undergoes two successive oxidations by NADP, the final one being an oxidative decarboxylation to form a pentose phosphate.
Diverges from this when glucose-6-phosphate is oxidized to ribose 5 phosphate by the enzyme glucose-6 phosphate dehydrogenase. This step reduces NADP to NADPH, generating a source of reducing power in cells for use in reductive biosyntheses.
In plants, part of the pathway functions in the formation of hexoses from carbon dioxide in photosynthesis. Also important as source of pentoses, for example for nucleic acid biosynthesis. This pathway is the main metabolic pathway in neutrophils, congenital deficiency in the pathway produces sensitivity to infection.
Alternative metabolic route to Embden Meyerhof pathway for breakdown of glucose.
(18 Nov 1997)
Warren shunt Anastomosis of the splenic end of the divided splenic vein to the left renal vein.
Synonym: distal splenorenal shunt.
(05 Mar 2000)
Waterston shunt Creation of a narrow (about 3 mm) opening between the ascending aorta and the subjacent right pulmonary artery to increase pulmonary circulation in cyanotic heart disease with decreased pulmonary flow.
(05 Mar 2000)
complications of ventriculo-peritoneal shunt <radiology> Kinking, interruption, exit from peritoneal cavity with growth, through processus vaginalis to scrotum, CSFoma, mass effect exhibited on bowel gas pattern with malfunctioning shunt, lack of movement of shunt tip with positional or temporal change, perforation of hollow viscus (e.g., bowel or bladder)
(12 Dec 1998)
portacaval shunt Surgical anastomosis between portal and systemic veins, surgical anastomosis between the portal vein and the vena cava, as in an Eck fistula.
(05 Mar 2000)
portacaval shunt, surgical Surgical portasystemic shunt between the portal vein and inferior vena cava.
(12 Dec 1998)
portasystemic shunt A shunt between any parts of the portal and systemic venous systems, including portacaval, mesocaval, splenorenal shunt's or spontaneously occurring shunt's.
(05 Mar 2000)
portasystemic shunt, surgical Surgical venous shunt between the portal and systemic circulation to effect decompression of the portal circulation. It is performed primarily in the treatment of bleeding oesophageal varices resulting from portal hypertension. Types of shunt include portacaval, splenorenal, mesocaval, splenocaval, left gastric-caval (coronary-caval), portarenal, umbilicorenal, and umbilicocaval.
(12 Dec 1998)
portasystemic shunt, transjugular intrahepatic A type of surgical portasystemic shunt to reduce portal hypertension with associated complications of oesophageal varices and ascites. It is performed percutaneously through the jugular vein and involves the creation of an intrahepatic shunt between the hepatic vein and portal vein. The channel is maintained by a metallic stent. The procedure can be performed in patients who have failed sclerotherapy and is an additional option to the surgical techniques of portocaval, mesocaval, and splenorenal shunts. It takes one to three hours to perform. (jama 1995;273(23):1824-30)
(12 Dec 1998)
hexose monophosphate shunt The main metabolic pathway in activated neutrophils, rendering them relatively insensitive to inhibitors of oxidative phosphorylation. Congenital deficiency of the first enzyme in the shunt, glucose 6 phosphate dehydrogenase, produces a sensitivity to infection similar to that seen in chronic granulomatous disease.
(18 Nov 1997)
Scribner shunt Connection of an artery, customarily the radial, to the cephalic vein via a short extracorporeal catheter.
(05 Mar 2000)
H shunt <surgery> A side-to-side shunt between adjacent vessels which utilises a connecting conduit.
Synonym: H graft.
(05 Mar 2000)
shunt 1. To turn to one side, to divert, to bypass.
2. <cardiology> A passage or anastomosis between two natural channels, especially between blood vessels. Such structures may be formed physiologically (for example to bypass a thrombosis) or they may be structural anomalies.
3. <surgery> A surgically created anastomosis, also, the operation of forming a shunt.
(18 Nov 1997)
shunt, left to right A term used to describe the diversion of blood from the higher pressure left side of the heart to the right side (pulmonary circuit). Can be seen in ventricular septal defect, atrial septal defect and patent ductus arteriosus (congenital at birth).
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á